The Food and Drug Administration issued draft guidance Jan. 6 on marketing submissions and lifecycle management for artificial intelligence-enabled devices. The guidance clarifies differences in terminology between the FDA and the AI device manufacturers and software developers. In addition, it provides recommendations on information needed throughout a product's life cycle for regulation of safety and efficacy.

Headline
An FBI report released Nov. 13 details actions by cyber actors weaponizing ARTEX, an open-source, large language model-driven agentic artificial intelligence…
Headline
The AHA will host a webinar Dec. 1 at 1 p.m. ET on how to create and build an effective artificial intelligence training program. Attendees will learn how to…
Headline
A Gallup survey published Nov. 9 on patient comfort with artificial intelligence in care found that 56% of U.S. adults who visited a primary care provider in…
Headline
Christine Moutier, M.D., chief medical officer at the American Foundation for Suicide Prevention, discusses the usage of artificial intelligence chatbots among…
Headline
Christine Moutier, M.D., chief medical officer at the American Foundation for Suicide Prevention, discusses the usage of artificial intelligence chatbots among…
Headline
The AHA Nov. 3 launched a new webpage, Artificial Intelligence Policy and Advocacy, featuring AHA policy letters, statements, fact sheets, news and other…